Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification
A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...
Takeda
Zhejiang Huahai Pharmaceutical Receives FDA Approval for Generic Vyvanse
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt...
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...
HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...
Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...
Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China
The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...
Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA
Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...
Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments
The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired...
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Zhejiang Suspends Generic Nesina Trading Due to IP Disputes
Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...
Takeda Posts Strong Q3 Results, Announces Pipeline Advances in Oncology and Rare Diseases
Japan-based pharmaceutical giant Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...
Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...